Daily ReportSep 11, 2026
Sepsis, September 11 edition
We read 41 papers and selected 3.
Summary
Today’s strongest sepsis studies span mechanistic discovery, evidence synthesis, and antimicrobial stewardship. A macrophage-derived IL-39 pathway was linked causally to sepsis severity in patients and experimental models, while a preregistered meta-analysis found a promising but statistically uncertain mortality signal for peripheral-perfusion-guided resuscitation. A randomized trial in Bangladesh showed that procalcitonin-guided antibiotic discontinuation substantially reduced antibiotic exposure without an observed increase in mortality or recurrent infection.
Research Themes
- Causal inflammatory mechanisms and therapeutic targets
- Perfusion-guided resuscitation and uncertainty in mortality effects
- Procalcitonin-guided antimicrobial de-escalation in resource-limited settings
Selected Articles
1. Interleukin-39 is a Prognostic Biomarker and Therapy Target for Sepsis.
Across two independent patient cohorts, circulating IL-39 was elevated at sepsis presentation and predicted 28-day survival. Single-cell and mouse experiments identified macrophage-derived IL-39 as a causal aggravator of sepsis through GP130-dependent MAPK/P38 signaling; genetic suppression or antibody neutralization was protective.
Impact: This study connects a clinically measurable biomarker with a validated, cell-specific pathogenic mechanism and therapeutic intervention. It advances IL-39 from an observational association to a candidate precision-treatment target.
Clinical Implications: Serum IL-39 could potentially support prognostic stratification at admission, while IL-39 neutralization or interruption of the IL-39–GP130 pathway may represent a future adjunctive therapy. Clinical use requires prospective validation, dose and timing studies, and confirmation of safety because excessive immune suppression could impair host defense.
Key Findings
- Serum IL-39 was significantly increased in septic patients across two independent cohorts and predicted 28-day survival.
- Single-cell sequencing localized the increased IL-39 signal primarily to macrophages.
- Recombinant IL-39 or macrophage-specific overexpression worsened sepsis in mice, whereas macrophage-specific deficiency, silencing, or neutralizing antibodies were protective.
- IL-39 aggravated inflammation through GP130-mediated MAPK/P38 signaling, and macrophage-specific GP130 deletion abrogated this effect.
Methodological Strengths
- Integrated evidence from two independent clinical cohorts, single-cell sequencing, genetic manipulation, viral modulation, and pharmacologic neutralization.
- The mechanistic pathway was tested with both gain-of-function and loss-of-function approaches, including macrophage-specific GP130 deletion.
Limitations
- The clinical biomarker findings are prognostic associations and do not establish that IL-39 measurement improves patient outcomes.
- The therapeutic experiments were conducted in septic mice, so human pharmacology, optimal treatment timing, and safety remain unestablished.
Future Directions: Prospective multicenter studies should validate IL-39 thresholds and incremental value beyond established severity scores. Translation should proceed through biomarker-enriched clinical trials of IL-39 or GP130 inhibition, with careful monitoring of pathogen clearance and secondary infections.
Sepsis remains a global health crisis with high mortality, due to a paucity of reliable diagnostic markers for accurate risk stratification and precision management. Interleukin-39 (IL-39), a novel immunomodulatory cytokine, plays an important role in regulating the pathophysiology of immunity, metabolism, and et al. Here, we observed significantly elevated serum IL-39 levels in septic patients at admission compared with non-sepsis ICU patients and healthy controls across two independent cohorts. Furthermore, circulating IL-39 concentrations could predict 28-days survival in patients with sepsis.
2. Mortality Effect of Peripheral Perfusion-Guided Resuscitation in Vasodilatory Shock: A Systematic Review and Dual Frequentist-Bayesian Meta-Analysis of Randomized Trials.
This preregistered systematic review included seven randomized trials involving 2,408 patients with septic shock. Peripheral-perfusion-guided resuscitation produced a mortality risk ratio of 0.87, which narrowly missed frequentist significance, while the Bayesian analysis estimated a 97.2% probability that the effect favored the intervention; the magnitude remains uncertain.
Impact: The study addresses an important resuscitation controversy using randomized evidence and a transparent dual statistical framework. Its negative or indeterminate frequentist result is scientifically valuable because it prevents premature adoption while quantifying a clinically relevant signal for future trials.
Clinical Implications: Peripheral perfusion measures may be reasonable adjuncts to current resuscitation assessment, but the evidence does not justify replacing standard care or lactate-based strategies. Clinicians should await adequately powered trials before changing mortality-focused protocols.
Key Findings
- Seven randomized controlled trials comprising 2,408 patients were included, with no detected statistical heterogeneity.
- The primary frequentist pooled risk ratio for 28-day mortality was 0.87 (95% confidence interval 0.76–1.01; P=0.06).
- The prespecified Bayesian analysis estimated a 97.2% posterior probability that the mortality risk ratio was below 1.
- The two largest and lowest-risk trials were individually nonsignificant, supporting uncertainty about the true treatment effect.
Methodological Strengths
- The review was preregistered with PROSPERO and followed PRISMA methods with formal risk-of-bias and certainty-of-evidence assessment.
- The prespecified frequentist and Bayesian analyses provide complementary interpretations of an intervention with a borderline mortality signal.
Limitations
- Only seven trials were available, and the confidence interval crossed the line of no effect.
- The included trials may differ in peripheral perfusion targets, co-interventions, patient selection, and adherence, limiting direct protocol generalizability.
Future Directions: Future multicenter randomized trials should use standardized peripheral perfusion targets, protocolized co-interventions, and sufficient power for mortality. Individual-patient-data analyses could identify phenotypes most likely to benefit and clarify interactions with lactate-guided resuscitation.
OBJECTIVES: To determine the effect of peripheral perfusion-guided resuscitation on 28-day mortality in adults with vasodilatory shock. DATA SOURCES: We searched PubMed, Embase, Cochrane Central Register of Controlled Trials, and Scopus from inception to November 2025. STUDY SELECTION: We included randomized controlled trials (RCTs) comparing peripheral perfusion-guided resuscitation with standard care or lactate-guided resuscitation; all eligible trials enrolled patients with septic shock. DATA EXTRACTION: Trial characteristics, intervention and comparator protocols, and outcomes were extracted.
3. Use of procalcitonin point-of-care testing to guide de-escalation of antibiotic therapy in adults with suspected bacterial sepsis in a tertiary hospital in Bangladesh: a randomised controlled open-label trial.
In this registered, open-label randomized trial of 532 adults with suspected bacterial sepsis in Bangladesh, daily procalcitonin-guided advice reduced median antibiotic duration from 9.0 to 4.7 days. Mortality was similar between groups, and recurrent infection was not increased, although the single-center trial was not powered to establish noninferiority for these safety outcomes.
Impact: This trial provides randomized evidence from a resource-limited setting where antimicrobial resistance and diagnostic constraints are substantial. It demonstrates a large reduction in antibiotic exposure while reporting no apparent increase in mortality or recurrent infection, directly informing stewardship strategies that may be feasible beyond high-income health systems.
Clinical Implications: Daily procalcitonin point-of-care testing can support antibiotic discontinuation after 72 hours in selected adults with suspected bacterial sepsis, provided that clinical reassessment and microbiological data remain central. Implementation should include safety monitoring, clinician override, and adaptation to local pathogen prevalence and test availability.
Key Findings
- Of 1,002 screened patients, 532 were randomized to procalcitonin-guided therapy or standard care, with 266 assigned to each group.
- Median antibiotic duration was 4.7 days with procalcitonin guidance versus 9.0 days with standard care (P<0.0001).
- Mortality was 8.7% in the procalcitonin group and 7.9% in the control group; the absolute risk difference was 0.8 percentage points (P=0.875).
- Recurrent infection occurred in 3.0% and 3.8% of participants, respectively, with no significant difference.
Methodological Strengths
- Randomized allocation, intention-to-treat analysis, trial registration, and prospective safety oversight strengthen causal interpretation.
- The intervention was tested in a real-world tertiary hospital in a low- and middle-income country, improving contextual relevance for antimicrobial stewardship.
Limitations
- The trial was open-label and conducted at a single center, which may introduce performance bias and limit generalizability.
- It was not powered to formally establish mortality noninferiority, and the non-binding advice allowed clinician behavior to vary.
Future Directions: Larger multicenter pragmatic trials should evaluate safety in defined sepsis subgroups, examine cost-effectiveness and antibiotic-resistance outcomes, and compare point-of-care testing with laboratory-based pathways. Implementation studies should determine how procalcitonin guidance can be integrated with clinical examination, cultures, and local antimicrobial policies.
BACKGROUND: Important drivers of antibiotic resistance in low- and middle-income countries (LMICs) include antibiotic overuse and scarcity of microbiological diagnostics. Procalcitonin point-of-care testing is a potential tool to guide antibiotic de-escalation in patients admitted with suspected bacterial sepsis. METHODS: In an open-label randomised controlled clinical trial in Chittagong Medical College Hospital in Bangladesh, adult patients with suspected bacterial sepsis were randomised to procalcitonin (PCT)-guided de-escalation of antibiotic therapy or standard-of-care. In the intervention group, serum procalcitonin was assessed daily and clinicians received a non-binding advice to stop antibiotics after 72 h if procalcitonin dropped below pre-defined threshold concentrations (0.5 ng/mL or 80% from the peak value if baseline value > 2 ng/mL).